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Familial tumoral calcinosis (FTC) refers to a heterogeneous group of inherited disorders characterized by the
occurrence of cutaneous and subcutaneous calcified masses. Two major forms of the disease are now
recognized. Hyperphosphatemic FTC has been shown to result from mutations in three genes: fibroblast
growth factor-23 (FGF23), coding for a potent phosphaturic protein, KL encoding Klotho, which serves as a co-
receptor for FGF23, and GALNT3, which encodes a glycosyltransferase responsible for FGF23 O-glycosylation;
defective function of any one of these three proteins results in hyperphosphatemia and ectopic calcification.
The second form of the disease is characterized by absence of metabolic abnormalities, and is, therefore,
termed normophosphatemic FTC. This variant was found to be associated with absence of functional SAMD9, a
putative tumor suppressor and anti-inflammatory protein. The data gathered through the study of these rare
disorders have recently led to the discovery of novel aspects of the pathogenesis of common disorders in
humans, underscoring the potential concealed within the study of rare diseases.
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Familial tumoral calcinosis (FTC) re-
presents a clinically and genetically
heterogeneous group of inherited dis-
eases manifesting with dermal and
subcutaneous deposition of calcified
materials. In recent years, the patho-
genesis of these disorders has been
elucidated, not only leading to delinea-
tion of the major pathways responsible
for regulating extraosseous calcifica-
tion, but also shedding new light on
the pathogenesis of pathologies as
common as renal failure and autoim-
mune diseases.
FAMILIAL TUMORAL CALCINOSIS:
HISTORICAL PERSPECTIVE
The first clinical description of familial
tumoral calcinosis (FTC) dates back to
1898 when two French dermatologists,
Giard and Duret, reported for the first
time the cardinal features of the dis-
order under the name endotheliome
calcifie´ (Giard, 1898; Duret, 1899).
The disease was later described in the
German literature as lipocalcinogranu-
lomatosis or Teutschlaender’s disease
after the German dermatologist who
studied a large number of such cases
(Tseutschlaender, 1935). The term tu-
moral calcinosis was coined in the
American literature by Inclan et al.
(1943). Inclan et al. were also the first
to accurately differentiate this inherited
disease from other related but acquired
conditions, which later became known
as metastatic calcinosis and dystrophic
calcinosis. Subsequently, numerous re-
ports, initially emanating from travelers
who had returned from Africa, indicated
that the disease is apparently prevalent
in this region of the world (McClatchie
and Bremner, 1969; Owor, 1972).
Despite these advances, it was not
until 1996 that Smack et al. formally
established the distinction between
normophosphatemic (NFTC) and hyper-
phosphatemic FTC (HFTC) (Smack
et al., 1996), a classification that proved
to be instrumental in guiding the
molecular studies that eventually led to
the identification of the genetic basis
of FTC.
FTC: EPIDEMIOLOGICAL, CLINICAL,
AND BIOCHEMICAL FEATURES
As mentioned above, FTC has been
mainly (but not exclusively) reported in
Africa, the Middle-East, and in popula-
tions originating from these regions of
the world. Its exact prevalence is
unknown, but it is considered to be
exceedingly rare. Although the disease
was initially reported to be inherited in
an autosomal dominant fashion (Lyles
et al., 1985), the recent identification of
the genetic defects underlying all forms
of FTC definitely established an auto-
somal recessive mode of inheritance
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(Topaz et al., 2004; Benet-Pages et al.,
2005; Ichikawa et al., 2005).
Serum phosphate levels demarcate
the two major subtypes of FTC: HFTC
(MIM211900) and NFTC (MIM610455;
Sprecher, 2007). Although these two
disorders were initially considered part
of a clinical continuum (Metzker et al.,
1988), it is today clear that they
represent distinct entities, not only at
the metabolic level, but also at the
clinical, epidemiological, and genetic
(see below) levels.
HFTC is generally characterized by
a relatively late onset from the first to
the third decade of life (Prince et al.,
1982; Metzker et al., 1988; Slavin
et al., 1993), although appearance of
calcified nodules has been reported as
early as at 6 weeks of age (Polykan-
driotis et al., 2004). It has been mainly
reported in individuals of Middle
Eastern and African origins (Metzker
et al., 1988; Slavin et al., 1993). Many
patients are often incidentally diag-
nosed while undergoing radiographic
investigation for unrelated reasons.
Slowly growing calcified masses devel-
op mainly at periarticular locations,
with a predilection for skin areas over-
lying large joints. The hips are most
often involved. These calcified masses
are initially asymptomatic, but progres-
sively reach large sizes (up to 1.5 kg),
thereby interfering with movements
around the joints (Figure 1a). Ulcera-
tion is usually accompanied by intol-
erable pain and is occasionally
associated with secondary infections,
rarely reported as a cause of death
(Sprecher, 2007). In some affected
individuals, extracutaneous signs may
predominate. Dental manifestations,
including pulp calcifications and oblit-
eration of the pulp cavity, may be
prominent (Burkes et al., 1991; Cam-
pagnoli et al., 2006; Specktor et al.,
2006); testicular microlithiasis has
been reported as part of the disease
(Campagnoli et al., 2006); angioid
streaks and corneal calcifications have
been observed as well (Ghanchi et al.,
1996); and bone manifestations (diaphy-
sitis and hyperostosis) may be more
common than initially thought (Clarke
et al., 1984; Mallette and Mechanick,
1987; Ballina-Garcia et al., 1996). HFTC
has been reported in association with
pseudoxanthoma elasticum (Mallette
and Mechanick, 1987). Recently, a
long-term follow-up study of one of the
largest HFTC kindreds described re-
vealed salient features of the disease,
including overall good prognosis, lack of
efficient treatments for the disorder apart
from surgical removal of calcified tu-
mors (most patients undergo over 20
major operations during their life time),
and possible association with hyperten-
sion and pulmonary restrictive disease
(Carmichael et al., 2009). Medical treat-
ment is notoriously frustrating. Isolated
reports have suggested benefit from
combined treatment of HFTC with
acetazolamide and sevelamer hydro-
chloride, a non-calcium phosphate bin-
der (Garringer et al., 2006; Lammoglia
and Mericq, 2009).
NFTC seems to be even less
prevalent than HFTC, with only six
families reported to date (Topaz et al.,
2006; Chefetz et al., 2008). The disease
often initially manifests with a nonspe-
cific erythematous rash and mucosal
inflammation during the first year of life
(Metzker et al., 1988; Katz et al., 1989).
Inflammatory manifestations in the oral
cavity can be particularly debilitating
(Gal et al., 1994). This eruption heralds
the progressive, but often rapid, devel-
opment of small, acrally located calci-
fied nodules, which almost invariably
lead to ulceration of the overlying skin
and discharge of chalky material (Fig-
ure 1b). Here too, unremitting pain and
infection are major causes of morbidity.
Histopathologically (Figure 1c), two
major stages in calcified tumor forma-
tion have been recognized: an active
phase characterized by the presence of
multinucleated giant cells and macro-
phages surrounding calcified deposits in
the dermis, and a chronic or inactive
phase associated with dense fibrous
tissue (Veress et al., 1976). Biochemical
analysis of extruded calcified masses
indicated that they are mainly com-
posed of calcium hydroxyapatite with
amorphous calcium carbonate and cal-
cium phosphate (Boskey et al., 1983).
As mentioned above, metabolic
abnormalities are the major features
distinguishing HFTC from NFTC.
HFTC patients invariably show
elevated levels of circulating phosphate
(in the range of 5 to 7mgdl1,
normal levels¼2.5–4.5mgdl1 or
0.80–1.44mmol), which are due to
decreased fractional phosphate excre-
tion through the kidney proximal tu-
bules (White et al., 2006). Calcium
levels are typically normal in HFTC,
and 1,25-dihydroxyvitamin-D levels
are normal or inappropriately elevated
(Steinherz et al., 1985). In contrast,
NFTC patients do not show any meta-
bolic abnormality (Metzker et al.,
1988; Topaz et al., 2006). In fact, these
differences are very much reminiscent
of the dichotomous nature of acquired
calcinosis (Touart and Sau, 1998).
Here, calcinosis can either manifest as
Figure 1. Clinical findings in FTC. (a) Computed tomographic scan showing a calcified mass in the soft
tissue adjacent to the right major Trochanter (red arrow). (b) Calcified tumor on the right wrist of a 5-year-
old boy with NFTC. (c) A skin biopsy obtained from an 8-year-old female patient with NFTC have
calcified materials in the upper and middle dermis (hematoxylin and eosin, 400). (d) Calcified nodules
in a 70-year-old patient with dermatomyositis and acquired calcinosis cutis.
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a result of an underlying metabolic
disorder as in chronic renal failure, or
develop as a reaction to tissue damage,
as in autoimmune diseases (Figure 1d)
or as in atherosclerosis (Touart and Sau,
1998). When cutaneous calcinosis is
due to deranged phosphate or calcium
metabolism (e.g., chronic renal failure),
it is termed metastatic calcinosis; by
contrast, when it is secondary to tissue
damage (e.g., autoimmune disease), it is
known as dystrophic calcinosis (Touart
and Sau, 1998). At this regard, clinical
and metabolic features of HFTC very
much resemble metastatic calcinosis,
while NFTC models dystrophic calcino-
sis, thus suggesting that elucidation of
the molecular basis of FTC may shed
light on the pathogenesis of these two
major forms of acquired calcinosis. This
assumption was the impetus that drove a
large international effort aimed at deci-
phering the molecular cause and bio-
chemical mechanisms underlying the
various forms of FTC.
MOLECULAR GENETICS OF HFTC
We owe to the study of rare diseases
the discovery of many key physiologi-
cal pathways (Antonarakis and Beck-
mann, 2006). In less than 5 years, the
study of FTC has revealed a surprisingly
intricate regulatory network of proteins
responsible for regulation of phosphate
homeostasis and extraosseous calcifi-
cation (Sprecher, 2007; Chefetz and
Sprecher, 2009).
Using homozygosity mapping,
HFTC was initially mapped to
2q24–q31 and found to be associated
with mutations in GALNT3, gene en-
coding a glycosyltransferase termed
UDP-N-acetyl-a-D-galactosamine-poly-
peptide N-acetylgalactosaminyltrans-
ferase-3 (ppGalNacT3; Topaz et al.,
2004). ppGalNacT3 catalyses the initi-
al step of O-glycosylation of serine and
threonine residues, and is ubiquitously
expressed (Ten Hagen et al., 2003;
Wopereis et al., 2006). ppGalNacT3 is
one of a family of 24 acetylgalactosa-
minyltransferases, which are expressed
in a tissue-specific manner and play an
important role in the development and
maintenance of a variety of tissues (Ten
Hagen et al., 2003). Most congenital
disorders of glycosylation result from
impaired N-glycosylation and are char-
acterized by pleiotropic clinical mani-
festations (Freeze, 2006); in this regard,
HFTC is unique in that it results from
abnormal O-glycosylation and seems
to be associated exclusively with ecto-
pic calcification.
More than 10 mutations have so far
been reported in GALNT3 (Topaz et al.,
2004; Ichikawa et al., 2005, 2006;
Campagnoli et al., 2006; Garringer
et al., 2006, 2007; Specktor et al.,
2006; Barbieri et al., 2007; Dumitrescu
et al., 2009; Laleye et al., 2008); all of
these are predicted or have been found
(Topaz et al., 2005) to result in loss of
function of ppGalNacT3. Deleterious
alterations in GALNT3 were also found
to underlie at least one additional
autosomal recessive syndrome, hyper-
ostosis–hyperphosphatemia syndrome
(MIM610233), which, as HFTC, is also
associated with elevated levels of
serum phosphate (Melhem et al.,
1970; Altman and Pomerance, 1971;
Mikati et al., 1981). This syndrome
manifests with episodes of excruciating
pain associated with swelling, along
the long bones. Despite the fact that
HFTC and hyperostosis–hyperphospha-
temia syndrome manifest phenotypi-
cally in two different tissues, skin and
bone, mutations in the same gene,
GALNT3, and in one instance, the very
same mutation (Frishberg et al., 2005),
were found to underlie both syndromes
(Ichikawa et al., 2007a; Dumitrescu
et al., 2009; Olauson et al., 2008; Gok
et al., 2009). Interestingly, coexistence
of the two diseases in one family has
been reported (Narchi, 1997; Nithya-
nanth et al., 2008). In fact, phenotypic
heterogeneity seems to be quite char-
acteristic of the HFTC group of dis-
eases, with a widely variable spectrum
of disease severity and tissue involve-
ment (Sprecher, 2007).
Large-scale screening of HFTC fa-
milies revealed that GALNT3mutations
cannot be found in all HFTC families.
In parallel, several groups noticed that
HFTC represents in many ways the
metabolic mirror image of another rare
disorder known as hypophosphatemic
rickets (Bastepe and Juppner, 2008).
Three genetic types of hypophosphate-
mic rickets have been described: X-
linked, autosomal recessive, and auto-
somal dominant hypophosphatemic
rickets, which were shown to be
caused by mutations in PHEX, DMP1,
and fibroblast growth factor-23
(FGF23), respectively (Juppner, 2007;
Bastepe and Juppner, 2008; Shaikh
et al., 2008). FGF23 encodes the
FGF23, a potent phosphaturic protein
responsible for promoting phosphate
excretion through kidney (Strom and
Juppner, 2008). DMP1 and PHEX func-
tion as negative regulators of the
activity of FGF23 (Quarles, 2008).
FGF23 mainly originates from miner-
alized tissues, although it has also been
detected in other tissues such as kid-
neys, liver, and brain (Yoshiko et al.,
2007). Recent data indicate that FGF23
signals through the FGFR1(IIIc) recep-
tor, which is converted into a func-
tional FGF23 receptor by Klotho
(Urakawa et al., 2006), a molecule
previously shown in mice to regulate
aging-related processes (Kurosu and
Kuro-o, 2008). Despite the fact that
activating mutations in FGFR3 have
been linked to hypophosphatemia
(Quarles, 2008), it seems that this
receptor does not mediate the renal
effects of FGF23 (Liu et al., 2008).
Assessment of HFTC patients with-
out GALNT3 mutations revealed that
while dominant gain-of-function muta-
tions in FGF23 result in hypophospha-
temic rickets, recessive loss-of-function
mutations in the same gene cause
HFTC (Araya et al., 2005; Benet-Pages
et al., 2005; Chefetz et al., 2005;
Larsson et al., 2005b; Lammoglia and
Mericq, 2009; Masi et al., 2009).
HFTC-causing mutations in FGF23 are
associated with a variety of biochem-
ical abnormalities such as abnormal
secretion of the intact molecule from
the Golgi (Benet-Pages et al., 2005) and
decreased FGF23 stability (Larsson
et al., 2005a; Garringer et al., 2008).
FGF23 activity is partially processed
intracellularly by subtilisin-like propro-
tein convertases at a consensus se-
quence between residues R179 and
S180 (Benet-Pages et al., 2004). Domi-
nant mutations associated with hypo-
phosphatemic rickets affect the
proteolytic site of FGF23, preventing
proper degradation of the molecule
(Shimada et al., 2002). In contrast,
HFTC-causing mutations in FGF23
have been shown to result in enhanced
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proteolytic processing of FGF23 (Lars-
son et al., 2005a; Garringer et al.,
2008). In addition, a recent study
showed that a missense mutation in
KL, encoding Klotho, also results in a
phenotype very much resembling
HFTC (Ichikawa et al., 2007b). This
mutation was found to result in de-
creased expression of Klotho and con-
comitant decreased FGF23 signaling,
leading to a severe form of HFTC
characterized by widespread cuta-
neous and visceral calcifications, dif-
fuse osteopenia, and sclerodactyly
(Ichikawa et al., 2007b).
PATHOGENESIS OF HFTC
In summary, (1) HFTC can be caused
by mutations in at least three genes
(GALNT3, FGF23, and KL); (2) loss-of-
function sequence alterations in
GALNT3 are associated with two dis-
tinct phenotypes, HFTC and HSS; and
(3) loss-of-function mutations in FGF23
also cause HFTC, while dominant gain-
of-function mutations in the same gene
are associated with hypophosphatemic
rickets (2000), which is also due to
mutations in DMP1 (Feng et al., 2006;
Lorenz-Depiereux et al., 2006) and
PHEX (Table 1 and Strom and Juppner,
2008). These findings raised the possi-
bility that these various molecules may
be part of a single physiological path-
way. Recent data lend support to this
hypothesis (Figure 2).
For decades, phosphate homeostasis
has been thought to be maintained
through concerted actions of parathyr-
oid hormone, which inhibits renal
phosphate reabsorption and mobilizes
bone calcium and phosphate, and 1,25-
hydroxyvitamin-D, which increases
phosphate transport across small intes-
tine (Schiavi and Moe, 2002; Quarles,
2008). More recently, a group of
proteins, known as phosphatonins, has
been shown to regulate phosphate
levels in the circulation independently
of calcium (Schiavi and Moe, 2002).
FGF23 is the phosphatonin that has
been best characterized so far.
As mentioned above, FGF23 signal-
ing is dependent on the presence of
Klotho (Kurosu and Kuro, 2009). Thus
FGF23 mainly targets organs expressing
Klotho such as parathyroid glands and
kidneys (Razzaque and Lanske, 2007).
FGF23 inhibits phosphate reabsorption
through the major sodium-phosphate
transporters, NaPi-IIa and NaPi-IIc,
thus allowing efficient counter-regula-
tion of excessive circulating levels of
phosphate (Saito et al., 2003;
Razzaque, 2009). FGF23 also sup-
presses CYP27B1, which catalyzes
1-a-hydroxylation of 25-hydroxy-vita-
min-D and activates CYP24, which
inactivates 1,25-hydroxyvitamin-D
(Liu and Quarles, 2007). Interestingly,
1,25-dihydroxyvitamin-D was found to
upregulate FGF23 expression in bone,
thereby establishing a novel endocrine
feedback loop between these two
hormones (Kolek et al., 2005; Saito
et al., 2005). Not only does FGF23
deficiency alter phosphate homeosta-
sis, it also leads to abnormal miner-
alization, suggesting that FGF23 plays a
role in bone formation (Sitara et al.,
2008), perhaps in a paracrine manner
since osteocytes in bone are the major
source of FGF23 (Yoshiko et al., 2007).
The clinical phenotype associated with
decreased Klotho activity very much
overlaps with that exhibited by FGF23-
deficient individuals, except for the fact
that HFTC caused by KL mutations is
associated with hypercalcemia as well
as elevated serum levels of parathyroid
hormone and FGF23 (Ichikawa et al.,
2007b). This may in fact relate to the
fact that Klotho plays major direct (e.g.,
Table 1. Genetic and phenotypic heterogeneity among disorders of phosphate metabolism associated with
abnormal ppGalNacT3 and FGF23 function
Disease OMIM Phenotype Gene (protein) Protein function
Hyperphosphatemic familial
tumoral calcinosis
211900 Calcified masses over large joints, occasionally
visceral calcifications
GALNT3
(ppGalNacT3)
Initiates mucin type
O-glycosylation
Hyperostosis
hyperphosphatemia
syndrome
610233 Repeated attacks of painful swellings of the long
bones; on radiography, cortical hyperostosis,
periosteal reaction, diaphysitis
GALNT3
(ppGalNacT3)
Initiates mucin type
O-glycosylation
Hyperphosphatemic familial
tumoral calcinosis
211900 Calcified masses over large joints, more frequent
visceral calcifications than with GALNT3 mutations
FGF23 (FGF23) Regulates phosphate
reabsorption
Autosomal dominant
hypophosphatemic rickets
193100 Growth retardation, osteomalacia, rickets, bone pain FGF23 (FGF23) Regulates phosphate
reabsorption
Hyperphosphatemic familial
tumoral calcinosis
211900 Widespread cutaneous and visceral calcifications,
diffuse osteopenia and sclerodactyly
KL (Klotho) Involved in the regulation of
phosphate and calcium levels
X-linked hypophosphatemic
rickets
307800 Growth retardation, osteomalacia, rickets, bone pain PHEX (PHEX) Protease, which regulates
FGF23 expression and bone
mineralization
Autosomal recessive
hypophosphatemic rickets
241520 Growth retardation, osteomalacia, rickets, bone pain DMP1 (DMP1) Regulates FGF23 expression
and bone mineralization
Epidermal nevus1 162900 Hyperkeratotic papules/plaques distributed in a linear
or segmental fashion
FGFR3 (FGFR3) Serves as receptor for fibroblast
growth factors such as FGF1
FGF23, fibroblast growth factor-23; ppGalNacT3, polypeptide N-acetylgalactosaminyltransferase-3.
1In selected cases of epidermal nevus, increased levels of FGF23 associated with hypophosphatemic rickets are observed due to end-organ gain-of-function
mutations.
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regulation of the secretion of the
parathyroid hormone) and indirect
(e.g., decreased 1,25-dihydroxy-
vitamin-D3 activity) roles in the main-
tenance of calcium homeostasis (Na-
beshima and Imura, 2008). Of note,
independently of regulation of phos-
phate and calcium homeostasis, Klotho
plays a number of other important roles
such as controlling insulin signaling
(Razzaque and Lanske, 2007; Kurosu
and Kuro-o, 2008; Nabeshima and
Imura, 2008). Taken altogether, these
data suggest that FGF23 mainly serves
as a counter-regulatory hormone to
offset the effect of excessive 1,25-
hydroxy-vitamin-D.
As mentioned above, activity of
FGF23 is mainly modulated by a poorly
understood process of proteolysis at a
furin-like convertase sequence motif.
PHEX and DMP1 may promote the
activity of the subtilisin-like protease(s)
responsible for mediating FGF23 clea-
vage (Quarles, 2008). More interest-
ingly, FGF23 was found to be a
substrate for ppGalNacT3-mediated
O-glycosylation. ppGalNacT3 was
found to catalyze the glycosylation of
the recognition site of subtilisin-like
proprotein convertase, thereby protect-
ing FGF23 from proteolysis (Kato et al.,
2006). FGF23 secretion was also found
to be dependent on ppGalNacT3-
mediated O-glycosylation (Kato et al.,
2006). Thus, since loss-of-function mu-
tations in GALNT3, FGF23, and KL all
result in decreased activity of FGF23, it
is not surprising that they also yield
overlapping phenotypes (Table 1).
Currently very little is known about
the factors regulating the expression of
GALNT3. Phosphate was found to
stimulate the expression and/or activity
of ppGalNacT3 (Chefetz et al., 2009) as
well as FGF23 (Saito et al., 2005),
while it induced a marked decrease in
the activity of 1-a-hydroxylase, thereby
decreasing the amount of active vita-
min-D3 (Perwad et al., 2005). Since
1,25-dihydroxyvitamin-D was shown
to decrease the expression of GALNT3
(Chefetz et al., 2009), this complex
feedback loop enables for restraining
the activity of FGF23 once it is no more
required, namely when phosphate level
is back to normal.
A major question, which remained
largely unanswered, is why does
HFTC-associated ectopic calcification
mainly affect cutaneous and subcuta-
neous tissues in the face of hyperpho-
sphatemia affecting equally all tissues.
Recent data have implicated FGF7,
another phosphatonin, which is se-
creted in response to hyperphosphate-
mia (characteristically found in HFTC;
Carpenter et al., 2005), is produced
exclusively in the dermis (auf demKel-
ler et al., 2004), and is capable of
triggering the activation of matrix me-
talloproteinases (MMPs; Putnins et al.,
1995; Shin et al., 2002; Simian et al.,
2001). Interestingly, MMPs have been
shown to mediate ectopic calcification
in vascular tissues (Satta et al., 2003;
Qin et al., 2006). Accordingly, fibro-
blasts derived from HFTC patients or
normal fibroblasts knocked down for
GALNT3 showed increased activation
of several key MMPs (Chefetz et al.,
2009).
MOLECULAR GENETICS OF NFTC
The fact that NFTC has so far been
reported exclusively among Yemenite
Jews suggested that a founder mutation
may underlie the disease in this com-
munity, which in turn allowed homo-
zygosity mapping to be used to locate
the disease gene. Through study of five
affected kindreds, the disease gene was
found to map to 7q21, confirming at
the genetic level the fact that NFTC and
HFTC (which maps to 2q) are two
separate non-allelic disorders, despite
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Figure 2. FTC-associated molecules and the regulation of phosphate homeostasis. Two genes have been
found to be associated with classical FTC, GALNT3 encoding ppGalNacT3 (1) and FGF23 encoding the
phosphatonin FGF23 (2). Increased phosphate levels upregulate the activity of ppGAlNacT3 (3) as well as
FGF23 (4). ppGalNacT3 thenO-glycosylates FGF23 (5), thereby protecting it from the proteolytic activity of
subtilisin-like proprotein convertases (SPC) (6). FGF23 then signals through its receptor in the presence of
Klotho (7), resulting in decreased transport of phosphate through the Na–Pi transporters (8) and inhibiting
vitamin-D1 hydroxylation (9). Since 1,25-dihydroxyvitamin-D acts by promoting phosphate absorption
through the small intestine (10), the effect of FGF23 on vitamin-D metabolism results in decreased entry of
phosphate into the circulation (11). In contrast, 1,25-dihydroxyvitamin-D augments FGF23 signaling (12),
but inhibits ppGalNacT3 expression (13), thereby establishing a double-regulatory feedback loop
mechanism. Of note, FGF23 influences bone mineralization (14). The entire system is also under the
regulation of parathyroid hormone, which promotes phosphate excretion through kidney (15) and
mobilizes phosphate from the bone (16), thus integrating calcium- and phosphate-regulatory systems. As a
consequence of hyperphosphatemia, FGF7 is induced (17), which results in expression and activation of
several MMPs (18), which are known to mediate ectopic calcification (19). Since FGF7 mainly originates
from the dermis, this may explain the propensity of ectopic calcification to develop in the skin in HFTC.
Additional elements involved in the regulation of FGF23 activity include PHEX and DMP1, which inhibit
FGF23 activity through still poorly understood mechanisms (possibly including a direct interaction between
them) (20). Loss-of-function mutations in the genes encoding these two molecules are associated with
increased FGF23 activity and hypophosphatemia.
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clinical similarities between them (To-
paz et al., 2006). Candidate gene
screening revealed initially a missense
mutation in SAMD9 segregating with
the disease phenotype in all families
(Topaz et al., 2006). The mutation was
found to result in SAMD9 protein
degradation, suggesting a loss-of-func-
tion effect (Topaz et al., 2006). In
agreement with these results, a second
nonsense mutation was later identified
in an additional kindred of Jewish
Yemenite origin (Chefetz et al., 2008).
Although at first, identification of two
mutations in SAMD9 causing a similar
phenotype may have been expected,
these data are surprising given the rarity
of the disease and the very small size of
the Jewish Yemenite population. In
fact, the occurrence of two indepen-
dent genetic events within a very close
and small population may reflect a
selection effect (Chefetz et al., 2008).
Unfortunately, very little is currently
known about the physiological func-
tion of SAMD9 so that no functional
rationale has been provided so far to
explain this effect.
PATHOGENESIS OF NFTC
SAMD9 is a 1,589-amino-acid cyto-
plasmic protein ubiquitously expressed
in all adult and fetal tissues except for
fetal brain and skeletal muscle (Topaz
et al., 2006; Li et al., 2007). Apart from
an N-terminal SAM domain, it lacks
homology to any known family of
proteins.
The fact that calcification in NFTC is
often preceded by an inflammatory
rash (Metzker et al., 1988; Katz et al.,
1989) suggests a role for SAMD9 in the
regulation of inflammation within the
skin. In line with this hypothesis, tumor
necrosis factor-a as well as osmotic
shock were found to induce SAMD9
expression in a p38- and NF-kB-
dependant manner (Chefetz et al.,
2008). This indicates that SAMD9
may be involved in tumor necrosis
factor-a-induced cell apoptosis. It is,
therefore, of interest to note that the
expression of SAMD9 was found to be
significantly downregulated in a large
proportion of tumors of various origins
(Li et al., 2007). Decreased expression
of SAMD9 was found to be associated
with increased cell proliferation and
decreased apoptosis (Li et al., 2007). In
addition, transfection of tumor cells
with SAMD9 was accompanied by
increased apoptotic activity, decreased
cell invasion in an in vitro assay, and
decreased cancer cell proliferation (Li
et al., 2007). Tumor cells overexpres-
sing SAMD9 formed tumor of a lower
volume as compared with wild-type
cells (Li et al., 2007). Altogether, these
data indicate that SAMD9 may function
as a tumor-suppressor gene. In support
of this hypothesis, recent data show
that myelodysplatic syndrome, acute
myeloid leukemia, and juvenile mye-
lomonocytic leukemia are associated
with a microdeletion on 7q21.3 span-
ning SAMD9, and its paralog, SAMD9L
(Asou et al., 2009). How are these two
putative functions of SAMD9 (anti-
inflammatory and tumor-suppressive)
mechanistically related is not yet
known.
RELEVANCE TO ACQUIRED
DISEASES
The data reviewed above indicate the
importance of ppGalNacT3, FGF23,
Klotho, and SAMD9 in the prevention
of abnormal calcification in peripheral
tissues. Their involvement in the patho-
genesis of relevant human pathologies
is currently the focus of intense re-
search efforts.
A growing body of evidence points
to extraosseous calcification as a major
cause or predictor of morbidity and
mortality in humans. Vascular calcifi-
cation has been shown to quite accu-
rately predict mortality, mainly due to
cardiovascular causes, in large cohorts
(Thompson and Partridge, 2004; Bar-
asch et al., 2006). Among factors that
have been known for long to be
associated with the propensity to de-
velop cardiovascular diseases, are ele-
vated levels of circulating phosphate
(Kestenbaum et al., 2005; Tonelli et al.,
2005; Giachelli, 2009), which has
been shown to induce ectopic calcifi-
cation (Jono et al., 2000). Hyperpho-
sphatemia is most likely acting
independently of more conventional
cardiovascular risk factors (Lippi et al.,
2009), suggesting that interventions
specifically directed at attenuating ex-
traosseous calcification may provide
substantial additional benefit to indivi-
duals at risk (Schmitt et al., 2006).
Several studies have asked whether the
newly discovered regulators of phos-
phate homeostasis have a predictive
value of their own for pathologies
known to be associated with elevated
levels of circulating phosphate.
Although FGF23 levels were found to
also correlate with mortality among
patients undergoing hemodialysis, to-
tal-body atherosclerosis in the general
population, and progression of chronic
renal disease, they were found to
predict outcome independently of
phosphate levels (Fliser et al., 2007;
Gutierrez et al., 2008; Mirza et al.,
2009); in contrast, FGF23 levels were
found to be associated with renal stone
formation only if due to increased
urinary excretion of phosphate (Rendina
et al., 2006).
These data suggest a potential ben-
efit for novel therapies based on
modulation of the activity of the
various molecules known to play a role
in the pathogenesis of inherited FTC.
Tetracyclines have been shown to
ameliorate the course of ectopic calci-
nosis (Robertson et al., 2003; Boulman
et al., 2005) as well as to inhibit the
activity of MMPs (Kim et al., 2005; Qin
et al., 2006), which may play a role in
the pathogenesis of FTC (Chefetz et al.,
2009). Interestingly, we were recently
able to show that doxycycline signifi-
cantly upregulates the expression of
ppGalNacT3 (Chefetz and Sprecher,
2009), suggesting the need to assess
the efficacy of tetracyclines in disorders
associated with deranged activity of the
ppGalNacT3–FGF23 axis.
CONCLUSIONS
The study of FTC phenotypes has led to
delineation of novel biochemical path-
ways of importance for maintenance of
phosphate balance. It exemplifies re-
markably the immense potential con-
cealed within the study of rare diseases,
for only through the study of human
subjects could the function of ppGal-
NacT3, FGF23, and Klotho have been
delineated. Indeed, although ppGal-
NacT3-deficient mice feature a normal
lifespan, show hyperphosphatemia,
and inappropriately normal levels of
1,25-dihydroxyvitamin-D3, in analogy
with what is seen in HFTC patients, the
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mice do not show ectopic calcifica-
tions and males are infertile, which
are not features of HFTC in humans
(Ichikawa et al., 2009). In contrast to
humans, FGF23-deficient mice have a
shortened lifespan and show growth
retardation, infertility, muscle atrophy,
hypoglycemia, and visceral calcifica-
tion (Kuro-o et al., 1997; Shimada
et al., 2004). In fact FGF23 mice
resemble very much Klotho-deficient
mice (Kuro-o et al., 1997), even though
Klotho deficiency manifests differently
in humans than FGF23 deficiency
(Ichikawa et al., 2007b). More interest-
ingly, SAMD9 does not exist at all in
the murine genome (Li et al., 2007).
Thus, through study of an exceedingly
rare phenotype the major regulatory
molecules of critical importance for
maintenance of phosphate homeostasis
and prevention of ectopic calcification
have been discovered and are on the
verge of being used to refine therapeu-
tic approaches to much more common
ailments in humans such as renal fail-
ure and autoimmune diseases.
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